Pharmaceutical companies are constantly evaluating the appropriate balance and presentation of risk and benefit information within promotional material. This has proved to be a constant challenge for pharmaceutical companies in regards to certain types of promotional material. This session will discuss some of the recent developments regarding how a product’s risk information could be communicated- with a focus on the presentation of risk information in materials directed towards consumers.
Learning Objective : Upon completion of this session, the participant should be able to:
Review historical disclosure of risk information in consumer directed advertising
Evaluate a study designed to assess an alternative approach to presenting risk information within broadcast direct-to-consumer (DTC) prescription drug ads
Discuss the pros and cons of a potential new risk presentation within broadcast DTC prescription drug ads
Speaker(s)
Speaker
Christine Novak, PharmD
Associate Director, Commercial Regulatory Affairs
Bristol-Myers Squibb, United States
Speaker
Dwight Alben Bowen, PharmD, RPh
Senior Lead (Director), US Advertising and Promotion Regulatory Affairs
Shire, United States
Speaker
John Kamp
Executive Director
Coalition For Healthcare Communication, United States
